Third, although our PK data indicated prolonged serum stability of HYAL-Fc and efficacy studies in immunocompetent models demonstrated acceptable safety profiles, a comprehensive evaluation in non-human primates would be essential to assess potential off-tumor effects in HA-rich tissues (e.g., synovium, skin) and FAP (e.g., bone marrow) or LRRC15 (e.g., hair follicles) expressing sites. Here, LRRC15 is linked to neoplasm.